A Phase 3 interventional study of Tocilizumab and Nintedanib in Systemic Sclerosis and Interstitial Lung Disease, sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-04-08.
Sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Scleroderma, Systemic with a site in Poland — 6 open to participants now, 9 under way, 4 of them phase 3. Scleroderma, Systemic · Poland.
Among the 26 studies in Scleroderma, Systemic with a site in Poland, this one is the 15th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2025, is one of 7 in phase 3, and was the 19th registered.
614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.
Browse Scleroderma, Systemic studies →6 of the 26 studies in Scleroderma, Systemic with a site in Poland are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Poland, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in Poland, United States, Argentina and 42 more countries
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in Poland, United States, Australia and 7 more countries
Ages 18+
Artiva Biotherapeutics, Inc. · Sites in Poland, United States, Brazil and 8 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Poland, United States, Belgium and 3 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is above the median of 37 across 450 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 92 across the 24 interventional studies, 295 across the 2 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 26 have an industry lead sponsor. The 10 most frequent:
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland is the lead sponsor of 10 studies on the registry; 7 are open to participants now.
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
3 of the studies in Scleroderma, Systemic with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
| NCT06843239Zura Bio IncTibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Scleroderma, Systemic with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy (methotrexate, mycophenolate mofetil) for 56 weeks.
Full title of the trial:
A multicentre clinical trial evaluating the safety and efficacy of the combination of nintedanib and tocilizumab compared to standard treatment in patients with systemic sclerosis and interstitial lung disease. Analysis with theranostic approach and assessment of cytokine activity, markers of inflammation and pulmonary fibrosis using computed tomography, positron emission tomography, and metabolome and transcriptome studies in selected patients. NINTOC-TU study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tocilizumab pre-filled syringe 162 mg subcutaneously once a week nintedanib tablets 150 mg twice a day or 2 x 100 mg a day
Drug: Tocilizumab · Drug: Nintedanib · Drug: Standard therapy
mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
Drug: Standard therapy
Tocilizumab 162 mg s.c./week
Nintedanib - established doses of nintedanib for adults in the treatment of ILD, also SSc-ILD: 2 x 150 mg daily, in the event of e.g. increased liver enzyme levels, poorer treatment tolerance (e.g. diarrhea), the dose can be reduced to 2 x 100 mg
mycophenolate mofetil stable dose from 1000 - 3000 mg daily tablet 500 mg or 250 mg regardless of the preparation (Mycofit, CellCept, Mycophenolate mofetil, Myfenax) or methotrexate 10-25 mg/week orally or subcutaneously as above, regardless of the preparation
Also known as: mycophenolate mofetil, methotrexate
The decrease in forced vital capacity (FVC) of the lungs
The decrease in forced vital capacity (FVC) of the lungs expressed in ml calculated after 56 weeks of treatment
Time frame: 56 weeks
Change in percent lung involvement
Change in percent lung involvement assessed by computed tomography (HRCT%) from baseline to assessment in 56 weeks of study
Time frame: 56 weeks
Assessment of absolute changes in DLCO
Assessment of absolute changes in DLCO at week 56 compared to baseline (baseline)
Time frame: 56 weeks
Assessment of the absolute changes in predicted FVC%
Assessment of the the absolute changes in predicted FVC% at week 56 from baseline
Time frame: 56 weeks
Change in the Six-minute walk test (6MWT) result
Change in the Six-minute walk test (6MWT) result at week 56 compared to the baseline value
Time frame: 56 weeks
Change in the Health Assessment Questionnaire-Disability Index (HAQ-DI) score
Change in the Health Assessment Questionnaire-Disability Index (HAQ-DI) score at week 56 (from min. 0 to max.3). Scores of 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.
Time frame: 56 weeks
A change in the patient's global assessment of disease activity
A change in the patient's global assessment of disease activity (Patient's Global Assessment - PtGA), assessment at week 56 - PtGA scoring on Visual Analog Scale from optimal condition - 0 mm (min) to 100 mm (max) - the worse condition.
Time frame: 56 weeks
A change in the physician's global assessment of disease activity
A change in the physician's global assessment of disease activity (Physician's Global Assessment - PGA), assessment at week 56 - PGA scoring on Visual Analog Scale from optimal condition - 0 mm (min) to 100 mm (max) - the worse condition.
Time frame: 56 weeks
Assessment of the absolute changes from baseline in total scores in St. George's Respiratory Questionnaire (SGRQ)
Assessment of the absolute changes from baseline in total scores in St. George's Respiratory Questionnaire (SGRQ) at 56 weeks. St. George's Respiratory Questionnaire (SGRQ) ranges from 1 to 100, where 0 indicates best health and 100 indicates worst health.
Time frame: 56 weeks
Assessment of absolute changes compared to baseline values on the modified Rodnan skin Score (mRSS)
Assessment of absolute changes compared to baseline values on the modified Rodnan skin Score (mRSS) at week 56. mRSS is a semiquantitative score, ranging from 0 (normal) to 3 (severe), used to evaluate the skin thickness in 17 different cutaneous sites (for a total score from 0 (good) to 51 (the worst condition).
Time frame: 56 weeks
Percentage of participants with threshold improvement from baseline in modified Rodnan skin Score (mRSS)
Percentage of participants with threshold improvement from baseline in modified Rodnan skin Score (mRSS) at week 56. mRSS is a semiquantitative score, ranging from 0 (normal) to 3 (severe), used to evaluate the skin thickness in 17 different cutaneous sites (for a total score from 0 (good) to 51 (the worst condition).
Time frame: 56 weeks
Percentage of participants with modified Rodnan skin Score (mRSS) improvement greater than or equal to (>/=) 20%, 40%, or 60%
Percentage of participants with modified Rodnan skin Score (mRSS) improvement greater than or equal to (\>/=) 20%, 40%, or 60% \[time frame: baseline to week 56\]. mRSS is a semiquantitative score, ranging from 0 (normal) to 3 (severe), used to evaluate the skin thickness in 17 different cutaneous sites (for a total score from 0 (good) to 51 (the worst condition).
Time frame: Time frame: from baseline to week 56
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.
Of 17 phase 3 interventional studies under Scleroderma, Systemic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 54. This study's planned 29 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Nintedanib
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland